- Home
- BRT vs ALLO Comparison
BRT vs ALLO Comparison
Compare BRT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- ALLO
- Stock Information
- Founded
- BRT 1972
- ALLO 2017
- Country
- BRT United States
- ALLO United States
- Employees
- BRT N/A
- ALLO N/A
- Industry
- BRT Real Estate Investment Trusts
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRT Real Estate
- ALLO Health Care
- Exchange
- BRT Nasdaq
- ALLO Nasdaq
- Market Cap
- BRT 281.9M
- ALLO 252.9M
- IPO Year
- BRT N/A
- ALLO 2018
- Fundamental
- Price
- BRT $14.33
- ALLO $1.23
- Analyst Decision
- BRT Strong Buy
- ALLO Buy
- Analyst Count
- BRT 2
- ALLO 11
- Target Price
- BRT $19.75
- ALLO $8.67
- AVG Volume (30 Days)
- BRT 64.8K
- ALLO 2.3M
- Earning Date
- BRT 11-06-2025
- ALLO 11-06-2025
- Dividend Yield
- BRT 7.14%
- ALLO N/A
- EPS Growth
- BRT N/A
- ALLO N/A
- EPS
- BRT N/A
- ALLO N/A
- Revenue
- BRT $98,001,000.00
- ALLO N/A
- Revenue This Year
- BRT N/A
- ALLO N/A
- Revenue Next Year
- BRT $4.12
- ALLO $100.00
- P/E Ratio
- BRT N/A
- ALLO N/A
- Revenue Growth
- BRT 1.30
- ALLO N/A
- 52 Week Low
- BRT $14.00
- ALLO $0.86
- 52 Week High
- BRT $20.22
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- BRT 42.50
- ALLO 51.07
- Support Level
- BRT $14.00
- ALLO $1.16
- Resistance Level
- BRT $14.66
- ALLO $1.35
- Average True Range (ATR)
- BRT 0.39
- ALLO 0.09
- MACD
- BRT -0.02
- ALLO 0.01
- Stochastic Oscillator
- BRT 26.73
- ALLO 62.90
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.